Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191086 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
A Phase 3 study, sponsored by Upsher-Smith Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT01191086 is a Phase 3 study that has completed, run by Upsher-Smith Laboratories. The registered enrollment target is 210 participants.
The verdict
NCT01191086, a Phase 3 study, has completed, sponsored by Upsher-Smith Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
Interventions
- DRUG USL255
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191086
The ClinicalTrials.gov registry entry for NCT01191086 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Upsher-Smith Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which USL255 is the first listed.
NCT01191086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01191086 about?
NCT01191086 is a clinical study titled "Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures". The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
What is the current status of trial NCT01191086?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2010-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01191086?
The interventions under investigation include: USL255 (DRUG).
Who is sponsoring clinical trial NCT01191086?
This trial is sponsored by Upsher-Smith Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.